Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Assets: 2019-2024

Historic Non-Current Assets for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $125.5 million.

  • 4D Molecular Therapeutics' Non-Current Assets rose 19.66% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 19.66%. This contributed to the annual value of $125.5 million for FY2024, which is 189.71% up from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Non-Current Assets is $125.5 million, which was up 189.71% from $43.3 million recorded in FY2023.
  • 4D Molecular Therapeutics' Non-Current Assets' 5-year high stood at $125.5 million during FY2024, with a 5-year trough of $5.7 million in FY2020.
  • Over the past 3 years, 4D Molecular Therapeutics' median Non-Current Assets value was $43.3 million (recorded in 2023), while the average stood at $70.0 million.
  • In the last 5 years, 4D Molecular Therapeutics' Non-Current Assets surged by 1,612.90% in 2021 and then tumbled by 57.48% in 2022.
  • 4D Molecular Therapeutics' Non-Current Assets (Yearly) stood at $5.7 million in 2020, then soared by 1,612.90% to $97.2 million in 2021, then slumped by 57.48% to $41.3 million in 2022, then increased by 4.76% to $43.3 million in 2023, then soared by 189.71% to $125.5 million in 2024.